Multiple Sistem Atrofisi

Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8:1172.

Köllensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25:2604.

Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12:264.

Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019; 142:744.

Chandiramani, V. A., Palace, J. & Fowler, C. J. How to recognize patients with parkinsonism who should not have urological surgery. Br. J. Urol. 80, 100–104 (1997)

Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3:93.

Yamanishi, T. et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int. J. Urol. 11, 88–96 (2004).

Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord 2022; 37:1131.

Panicker JN, Simeoni S, Miki Y, et al. Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord? J Neurol 2020; 267:659.

Plazzi G, Corsini R, Provini F, et al. REM sleep behavior disorders in multiple system atrophy. Neurology 1997; 48:1094.

Bak TH, Crawford LM, Hearn VC, et al. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005; 11:268.

Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25:1077.

Sakakibara, R. et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J. Auton. Nerv. Syst. 79, 191–195 (2000).

Sakakibara, R. et al. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin. Auton. Res. 13, 106–108 (2003).

Batla A, De Pablo-Fernandez E, Erro R, et al. Young-onset multiple system atrophy: Clinical and pathological features. Mov Disord 2018; 33:1099.

Boudes, M. et al. Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov. Disord. 28, 347–355 (2013).

Sakakibara, R. et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? Journal of Neurology, Neurosurgery, and Psychiatry 68, 65–69 (2000).

Yamamoto, T. et al. Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov. Disord. 24, 972–978 (2009).

Sakakibara, R. et al. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin. Auton. Res. 13, 51–53 (2003).

Mathias, C. J., Fosbraey, P., da Costa, D. F., Thornley, A. & Bannister, R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br. Med. J. 293, 353–354 (1986).

Sakakibara, R., Hattori, T., Uchiyama, T. & Yamanishi, T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 71, 600–606 (2001).

Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167–178 (2002).

Sakakibara, R., Panicker, J., Finazzi-Agro, E., Iacovelli, V. & Bruschini, H. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol. Urodyn. 5, 551–563 (2015).

Groen, J. et al. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur. Urol. 69, 324–333 (2016).

Robinson, D. & Cardozo, L. Antimuscarinic drugs to treat overactive bladder. BMJ 344, e2130 (2012).

Department of Health & Human Services, U. S. U. S. Food & Drug administration http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269509.htm (2011).

Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8:1172.

Köllensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25:2604.

Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12:264.

Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019; 142:744.

Chandiramani, V. A., Palace, J. & Fowler, C. J. How to recognize patients with parkinsonism who should not have urological surgery. Br. J. Urol. 80, 100–104 (1997)

Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3:93.

Yamanishi, T. et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int. J. Urol. 11, 88–96 (2004).

Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord 2022; 37:1131.

Panicker JN, Simeoni S, Miki Y, et al. Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord? J Neurol 2020; 267:659.

Plazzi G, Corsini R, Provini F, et al. REM sleep behavior disorders in multiple system atrophy. Neurology 1997; 48:1094.

Bak TH, Crawford LM, Hearn VC, et al. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005; 11:268.

Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25:1077.

Sakakibara, R. et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J. Auton. Nerv. Syst. 79, 191–195 (2000).

Sakakibara, R. et al. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin. Auton. Res. 13, 106–108 (2003).

Batla A, De Pablo-Fernandez E, Erro R, et al. Young-onset multiple system atrophy: Clinical and pathological features. Mov Disord 2018; 33:1099.

Boudes, M. et al. Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov. Disord. 28, 347–355 (2013).

Sakakibara, R. et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? Journal of Neurology, Neurosurgery, and Psychiatry 68, 65–69 (2000).

Yamamoto, T. et al. Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov. Disord. 24, 972–978 (2009).

Sakakibara, R. et al. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin. Auton. Res. 13, 51–53 (2003).

Mathias, C. J., Fosbraey, P., da Costa, D. F., Thornley, A. & Bannister, R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br. Med. J. 293, 353–354 (1986).

Sakakibara, R., Hattori, T., Uchiyama, T. & Yamanishi, T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 71, 600–606 (2001).

Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167–178 (2002).

Sakakibara, R., Panicker, J., Finazzi-Agro, E., Iacovelli, V. & Bruschini, H. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol. Urodyn. 5, 551–563 (2015).

Groen, J. et al. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur. Urol. 69, 324–333 (2016).

Robinson, D. & Cardozo, L. Antimuscarinic drugs to treat overactive bladder. BMJ 344, e2130 (2012).

Department of Health & Human Services, U. S. U. S. Food & Drug administration http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269509.htm (2011).